Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Alter SA

Lawmaker Seeks To Interrogate Valeant Workers On Philidor

Rep. Elijah Cummings (D-MD), the ranking member of the House Committee on Oversight and Government Reform, wants to talk to the Valeant Pharmaceuticals International Inc. employees who reportedly helped set up Philidor Rx Services Inc., the specialty pharmacy the drug company recently broke ties with after some questionable business practices came to light.

Will new EU rules on trade secrets affect trial data disclosure?

Companies operating in the EU will have better protection against the theft or misuse of trade secrets such as manufacturing processes and specific technology, together with a new EU-wide definition of a trade secret, under draft rules passed yesterday by the European Parliament's legal affairs committee.


Court: Actavis' Namenda hard switch 'coercion,' 'anticompetitive'

A three-judge panel from the US Court of Appeals for the Second Circuit in New York on 22 May upheld a lower court's ruling ordering Actavis to keep its twice-daily immediate-release version of its Alzheimer's drug Namenda (memantine hydrochloride) on the US market – declaring the firm's plan for a "forced switch" to a newer version before generics are available is "coercion" and "anticompetitive."


Actavis Namenda case could trigger more 'product hopping' scrutiny

Actavis tried to persuade a three-judge panel from the US Court of Appeals for the Second Circuit in New York on 13 April to lift an injunction imposed by a lower court preventing the company from pulling its twice-daily immediate-release version of its Alzheimer's dementia drug Namenda (memantine hydrochloride) from the US market in light of a more updated form of the medicine.

See All

Company Information

  • Industry
  • Miscellaneous
  • Services